November 25th 2024
Fluorescence spectroscopy offers unique advantages for characterizing EVs.
November 22nd 2024
November 21st 2024
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Gallus BioPharmaceuticals Uses ambr15 Micro Bioreactor to Develop Novel Antibodies and Biosimilars
April 30th 2014TAP Biosystems announced that Gallus BioPharmaceuticals is using its ambr15 micro bioreactor system to optimize process development and clone selection of novel antibody therapeutics and biosimilars.